What's Trending in Stocks Right Now
Discover which stock market news stories are capturing the most attention today. This page shows you the most-viewed articles on StockTitan, updated every minute based on real visitor traffic. See what tens of thousands of traders and investors are reading right now.
Why this matters: When a news story suddenly gets massive readership, it often indicates significant market interest in that stock or sector. By tracking the most popular articles, you can quickly identify which companies and events are drawing investor attention and potentially moving markets.
This isn't editorial content or sponsored placement—it's based purely on reader activity. Every story below earned its position through actual page views from real visitors, making this an authentic snapshot of what the trading community finds most interesting. Whether it's earnings reports, FDA decisions, merger news, or market analysis, the most-read stories rise to the top.
Updated Every Minute: Market sentiment shifts quickly. This ranking is recalculated every 60 seconds to reflect the latest reading trends. What's trending now could be completely different in an hour as new stories break and capture attention.
Hyperscale Data (NYSE American: GPUS) announced that subsidiary Omnipresent Robotics has begun production, via a partner, of the first 30 OPR-R2 humanoid robots. These units are expected to be assembled and deployed at the company’s Michigan AI data center campus in Q3 2026.
This initial batch is part of a planned 143-robot fleet supporting a 100,000-square-foot Robotics Research, Testing and Innovation Center. The robots will aid data collection, model training, simulation validation, and embodied AI development using NVIDIA-based infrastructure.
- Production started for first 30 OPR-R2 humanoid robots
- Initial 30 robots targeted for deployment in Q3 2026
- Planned fleet totals 143 humanoid robots at Michigan Campus
- 100,000-square-foot Robotics Research, Testing and Innovation Center planned
- Laboratory to support training and testing of advanced AI foundation models
- Use of NVIDIA-based infrastructure for simulation, training and robotics workloads
- None.
FreeCast (Nasdaq: CAST) expanded its relationship with DIRECTV, making DIRECTV services a core integrated subscription option across FreeCast’s direct-to-consumer and Platform-as-a-Service ecosystems.
The integration lets residential and enterprise partners bundle DIRECTV within self-branded streaming, broadband, wireless, hospitality, and community offerings, aiming to drive recurring subscription revenue and enhance FreeCast’s unified entertainment platform.
- DIRECTV becomes core integrated subscription across FreeCast residential and PaaS ecosystems
- Partners can bundle DIRECTV with streaming, broadband, wireless, hospitality, and community offerings
- Management highlights DIRECTV as an immediate recurring-revenue opportunity for FreeCast and partners
- Integration leverages existing sales and distribution channels without new product development
- Expanded relationship supports FreeCast’s strategy to grow subscription-based monetization across multiple verticals
- None.
Intellia Therapeutics (Nasdaq: NTLA) reported additional positive Phase 3 HAELO data for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema.
Lonvo-z achieved an 87% reduction in mean monthly attacks vs placebo and showed large decreases in treated and moderate/severe attacks, improved AE-QoL scores, favorable safety, and supports a rolling BLA with a potential U.S. launch targeted for 1H 2027.
- Mean monthly HAE attacks reduced by 87% vs placebo during weeks 5–28
- 62% of lonvo-z patients attack free and therapy free vs 11% on placebo
- 89% reduction in attacks needing on-demand treatment vs placebo, weeks 5–28
- 91% reduction in moderate/severe attacks vs placebo, weeks 5–28
- AE-QoL score improved by 17.04 points vs placebo at week 28
- No serious adverse events observed in the lonvo-z treatment arm
- Rolling BLA for lonvo-z started with FDA; U.S. launch targeted 1H 2027
- Higher rates of mild/moderate infusion reactions and headaches vs placebo
- Fatigue, back pain and upper respiratory infections more frequent than placebo
The June 12, 2026 commentary describes how the orbital economy enters a new public-market phase as SpaceX (NASDAQ: SPCX) begins trading and commercial-space names join major indexes.
It highlights roles of Redwire (NYSE: RDW), Starfighters Space (NYSE: FJET), Rocket Lab, Intuitive Machines and Velo3D across the sector.
- None.
- None.
Rezolve Ai (NASDAQ:RZLV) plans to seek shareholder approval on June 30, 2026 for a capital reduction and a share repurchase agreement with BTIG, enabling buybacks of up to $300 million of ordinary shares.
Repurchases would start after expected UK Court approval by late August, initially using existing cash, with the company evaluating additional non-dilutive financing and strategic capital initiatives. The program is discretionary and may be modified or suspended.
- Board backing for up to $300 million share repurchase authority
- Initial repurchases expected to use existing cash reserves, limiting dilution
- Evaluating non-dilutive financing to support buybacks and growth investments
- Flexible structure to buy shares via BTIG using multiple trading methods
- Buyback contingent on shareholder and UK Court approvals
- No assurance on completion, timing, terms or amount of repurchases
- Non-dilutive financing and strategic capital initiatives remain uncertain
Rhythm Pharmaceuticals (Nasdaq:RYTM) reported positive interim six‑month data from a Phase 2 trial of setmelanotide in patients with Prader‑Willi syndrome (PWS) presented at ENDO 2026.
Among 17 patients, results showed mean BMI reductions, fat mass loss with preserved lean mass, improved hyperphagia and anxiety measures, and safety consistent with the known profile, supporting advancement to Phase 3.
- Mean BMI reduction of 3.06% at Month 6 (N=17)
- Adult BMI fell 3.11%; four of 10 cut BMI by >4%
- Pediatric BMI z-score mean reduction 0.35; five of seven >0.2
- Mean fat mass down 4.19%, lean mass up 0.74% (n=16)
- Six of nine adults saw >5% fat mass reduction
- Eight of 10 with severe hyperphagia had ≥7-point HQ-CT improvement
- Ten of 15 with elevated PADQ scores improved ≥11 points
- Safety and tolerability aligned with established setmelanotide profile
- None.
Agios (Nasdaq: AGIO) presented detailed 52-week Phase 3 RISE UP results for oral PK activator mitapivat in sickle cell disease at EHA 2026.
Mitapivat showed statistically significant hemoglobin responses, clinically meaningful reductions in transfusion burden and healthcare utilization for hemoglobin responders, and a safety profile similar to placebo with no treatment-related deaths.
- 40.6% hemoglobin response rate with mitapivat vs 2.9% with placebo (p<0.0001)
- 41.1% relative reduction in proportion requiring transfusions vs placebo (23.9% vs 40.6%)
- 55.9% relative reduction in average RBC units transfused per patient (0.70 vs 1.59)
- Hemoglobin responders: 26% lower annualized SCPC rate vs non-responders (2.20 vs 2.98)
- Hemoglobin responders: 34% fewer SCPC-related hospitalizations (1.16 vs 1.76)
- Hemoglobin responders: 53% fewer SCPC-related ER visits (1.11 vs 2.33)
- Hemoglobin responders: 37% fewer SCPC hospitalization days (7.83 vs 12.34)
- Fatigue improvement in hemoglobin responders exceeded 4.1-point clinically meaningful threshold (-5.19 vs -2.55)
- Mitapivat safety similar to placebo (treatment-emergent AEs 97.1% vs 98.6%); no treatment-related deaths
- Primary endpoint of SCPC rate reduction vs placebo did not reach statistical significance overall
- No overall difference between mitapivat and placebo for key secondary patient-reported fatigue endpoint
- High incidence of treatment-emergent adverse events in both arms (97.1% mitapivat; 98.6% placebo)
Incyte (Nasdaq: INCY) reported pivotal Phase 3 frontMIND results for tafasitamab (Monjuvi/Minjuvi) plus lenalidomide added to R-CHOP in previously untreated high-risk DLBCL and HGBL.
Tafa-Len-R-CHOP cut risk of progression or death by 25%, improved PFS and EFS, raised MRD-negativity rates, and showed manageable but higher Grade ≥3 and fatal adverse events, supporting global regulatory applications.
- Tafa-Len-R-CHOP reduced risk of progression or death by 25% (HR 0.75, P=0.0194)
- Two-year PFS 71.1% vs 62.9%; three-year PFS 67.3% vs 60.7% with R-CHOP
- Event-free survival improved with HR 0.79 (P=0.0260)
- MRD-negativity 81.3% with Tafa-Len-R-CHOP vs 66.7% with R-CHOP
- Fewer overall deaths with Tafa-Len-R-CHOP: 18.5% vs 21.7% with R-CHOP
- Data support global regulatory applications for tafasitamab and lenalidomide plus R-CHOP
- Grade ≥3 treatment-emergent adverse events 86.7% with Tafa-Len-R-CHOP vs 76.1% with R-CHOP
- Higher fatal TEAEs: 5.9% with Tafa-Len-R-CHOP vs 3.8% with R-CHOP
- Interim overall survival benefit not statistically significant (HR 0.85, P=0.2703)
Quantum Cyber (Nasdaq: QUCY) terminated its at-the-market sales agreement with Maxim Group, effective June 7, 2026, after not using the facility for two months.
Following over $15 million in May 2026 warrant proceeds, the company reports a debt-free capital structure, no exercisable warrants, and believes existing cash will fund its disclosed technology, R&D, and acquisition pipeline.
- Over $15 million in warrant exercise proceeds received in May 2026
- Debt-free capital structure with no exercisable warrants outstanding
- ATM equity facility terminated, removing reliance on at-the-market issuance
- Management believes current cash runway funds disclosed technology and acquisition pipeline
- None.